As discussed above, 3 of the 17 DMD biomarkers that were elevated in DMD patients relative to controls, and also responded to GC treatment, were linked by other studies to inflammation and the innate immune response (e.g. Fibrinogens, ANGPT2 and COL12). The gene discussed is ANGPT2; the disease is Duchenne muscular dystrophy.